Syntimmune Closes $50 Million Series B Financing led by Apple Tree Partners
Syntimmune, Inc., a clinical-stage biotechnology company focused on FcRn biology, today announced a $50 million Series B financing led by Apple Tree Partners, which has committed $48 million to the round, with additional participation from other existing investors. The funds from the Series B financing will further advance Syntimmune’s clinical development program.
Most Recent Posts:
The Medically Engineered Solutions in Healthcare (MESH) Incubator: A case study of innovation “push”
In an opinion piece for STAT, Marc Succi, MD, Clinician-in-Residence at Mass General Brigham Innovation, addresses the…
2022 World Medical Innovation Forum | Day 3 Recap
The final day of the World Medical Innovation Forum began with a discussion on the fast-moving landscape…
2022 World Medical Innovation Forum | Day 2 Recap
Day 2 of World Medical Innovation Forum kicked off with a fireside chat with FDA commissioner Robert…
